BioprintingFinancial ReportsMedical

Lab-on-a-Printer developer Aspect Biosystems receives $1M investment from Genome BC

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Canadian biotechnology company Aspect Biosystems has received a $1 million investment from  Genome BC, a Vancouver-based non-profit dedicated to genomics innovation. The funding will go towards advancing and further commercializing Aspect Biosystems’ 3D bioprinting and tissue engineering platform.

Since its founding in 2013, privately held Aspect Biosystems has been a key player in bioprinting technologies within Canada. It has gained considerable acclaim for its Lab-on-a-Printer 3D bioprinting platform which is capable rapidly fabricating functional, highly complex living tissues.

The system itself comprises of Aspect’s RX1 bioprinter machine, its innovative biomaterials and its disposable microfluidic printhead cartridges—the so-called “heart” of its Lab-on-a-Printer technology. By employing a coaxial flow focusing method, cell-laden bio fibers are generated within the cartridges in a specific 3D pattern. According to the company, “This unique 3D printing mechanism opens entirely new doors in the design of 3D printed tissue by allowing multiple different cell types to be precisely located or combined seamlessly during printing.”

genome bc

Understandably, Aspect’s microfluidics bioprinting technology has drawn interest from a range of pharmaceutical and biotech companies, which have recognized the technology’s broad potential for therapeutic applications, including predictive drug testing platforms and transplantable tissue therapeutics. Vancouver’s Genome BC is one such organization.

“Genome BC’s investment in Aspect Biosystems will provide funds to further their commercialization initiatives including partnership activities as well as development of their platform technology,” said Dr. Tony Brooks, Chief Financial Officer and Vice President of Entrepreneurship and Commercialization at Genome BC. “Aspect has shown significant commercial traction in a very short period of time and we are pleased to support their continued growth.”

Genome BC’s investment was made possible through its Industry Innovation (I²) program, which seeks to provide financial support for companies in the process of developing and commercializing life science technologies which could positively impact key sectors in British Columbia. The funding provided through I² is specifically given to “promising technologies…at early stages of commercial development.”

“Genome BC is playing an instrumental role in accelerating British Columbia’s most promising life science innovations and we are thrilled to have their support,” commented Tamer Mohamed, President and CEO of Aspect Biosystems. “With this additional financing, we are further increasing our capacity to meet key commercial demands and continuing our rapid growth as we work towards enabling the creation of human tissues on demand.”

In addition to the $1 million in funding which will bolster its bioprinting platform, Aspect Biosystems is also expanding its reach into the medical field by establishing partnerships with pharmaceutical, biotech, and healthcare companies, as well as research groups and institutions. By working together with experts across various medical segments, the Canadian biotech company is aiming to accelerate the development—and ultimately adoption—of its next-gen tissue engineering technology.

Research 2021
Ceramic AM Market Opportunities and Trends

This market study from 3dpbm Research provides an in-depth analysis and forecast of the ceramic additive ma...

Tess Boissonneault

Tess Boissonneault is a Montreal-based content writer and editor with five years of experience covering the additive manufacturing world. She has a particular interest in amplifying the voices of women working within the industry and is an avid follower of the ever-evolving AM sector. Tess holds a master's degree in Media Studies from the University of Amsterdam.

Related Articles

Back to top button

We use cookies to give you the best online experience and for ads personalisation. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services



Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*